MX2022002636A - Tratamiento de la enfermedad o trastorno hepatico que comprende los antagonistas del receptor de actrii. - Google Patents
Tratamiento de la enfermedad o trastorno hepatico que comprende los antagonistas del receptor de actrii.Info
- Publication number
- MX2022002636A MX2022002636A MX2022002636A MX2022002636A MX2022002636A MX 2022002636 A MX2022002636 A MX 2022002636A MX 2022002636 A MX2022002636 A MX 2022002636A MX 2022002636 A MX2022002636 A MX 2022002636A MX 2022002636 A MX2022002636 A MX 2022002636A
- Authority
- MX
- Mexico
- Prior art keywords
- disorder
- treatment
- liver disease
- actrii
- receptor antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962895107P | 2019-09-03 | 2019-09-03 | |
| PCT/IB2020/058114 WO2021044287A1 (en) | 2019-09-03 | 2020-09-01 | Treatment of liver disease or disorder comprising actrii receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002636A true MX2022002636A (es) | 2022-03-25 |
Family
ID=72422213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002636A MX2022002636A (es) | 2019-09-03 | 2020-09-01 | Tratamiento de la enfermedad o trastorno hepatico que comprende los antagonistas del receptor de actrii. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220340668A1 (https=) |
| EP (1) | EP4025248A1 (https=) |
| JP (1) | JP7663559B2 (https=) |
| KR (1) | KR20220054608A (https=) |
| CN (1) | CN114630681A (https=) |
| AU (1) | AU2020341135A1 (https=) |
| BR (1) | BR112022003884A2 (https=) |
| CA (1) | CA3153062A1 (https=) |
| IL (1) | IL290852A (https=) |
| JO (1) | JOP20220057A1 (https=) |
| MX (1) | MX2022002636A (https=) |
| WO (1) | WO2021044287A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| JP2025529933A (ja) * | 2022-08-26 | 2025-09-09 | バーサニス・バイオ・インコーポレイテッド | ＡｃｔＲＩＩ抗体固定単位用量の治療 |
| CN117577330B (zh) * | 2024-01-15 | 2024-04-02 | 北京大学 | 预测非酒精性脂肪性肝病肝纤维化程度的装置及存储介质 |
| WO2025183966A1 (en) | 2024-02-28 | 2025-09-04 | Versanis Bio, Inc. | Actrii antibodies with extended half life |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050186593A1 (en) | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| JP4544742B2 (ja) | 1998-05-06 | 2010-09-15 | メタモーフイクス・インコーポレーテツド | Ｇｄｆ−８の阻害による糖尿病の処置法 |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| PE20120532A1 (es) * | 2009-04-27 | 2012-05-18 | Novartis Ag | ANTICUERPOS ANTI-ActRIIB |
| AU2010315245B2 (en) * | 2009-11-03 | 2016-11-03 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| KR101461706B1 (ko) * | 2011-04-04 | 2014-11-18 | 한국생명공학연구원 | Ｄｌｋ１ 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2ｂ 억제제 |
| CN104513213A (zh) | 2013-09-28 | 2015-04-15 | 山东亨利医药科技有限责任公司 | Fxr激动剂 |
| EP3116878A4 (en) | 2014-03-13 | 2018-02-14 | Salk Institute for Biological Studies | Fxr agonists and methods for making and using |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| CN111662297A (zh) | 2014-11-21 | 2020-09-15 | 阿卡纳治疗学有限公司 | 用于治疗疾病的稠合双环化合物 |
| EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| WO2016103037A1 (en) | 2014-12-22 | 2016-06-30 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| WO2017078928A1 (en) | 2015-11-06 | 2017-05-11 | Salk Institute For Biological Studies | Fxr agonists and methods for making and using |
| CN106946867B (zh) | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
| WO2017128896A1 (zh) | 2016-01-26 | 2017-08-03 | 江苏豪森药业集团有限公司 | Fxr激动剂及其制备方法和应用 |
| WO2017143134A1 (en) | 2016-02-19 | 2017-08-24 | Alios Biopharma, Inc. | Fxr modulators and methods of their use |
| US20170240639A1 (en) | 2016-02-22 | 2017-08-24 | Acceleron Pharma Inc. | Actrii antagonists for use in increasing immune activity |
| WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| US10183872B2 (en) | 2016-06-13 | 2019-01-22 | Qi Wang | Counter circulating liquid processing system by repeatedly re-using thermal energy |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| US11091482B2 (en) | 2016-08-23 | 2021-08-17 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators |
| CN108430998B (zh) | 2016-09-28 | 2021-07-09 | 四川科伦博泰生物医药股份有限公司 | 氮杂双环衍生物及其制备方法和用途 |
| MX2019003790A (es) | 2016-10-04 | 2019-09-26 | Enanta Pharm Inc | Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos. |
| CN107973790A (zh) | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
| WO2018081285A1 (en) | 2016-10-26 | 2018-05-03 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof |
| CN108017636A (zh) | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| JOP20190152A1 (ar) | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
| CN109071468B (zh) | 2017-01-20 | 2022-09-02 | 四川科伦博泰生物医药股份有限公司 | 一种杂环化合物及其制备方法和用途 |
| WO2018190643A1 (en) | 2017-04-12 | 2018-10-18 | Il Dong Pharmaceutical Co., Ltd. | An isoxazole derivatives as nuclear receptor agonists and used thereof |
| US11339147B2 (en) | 2017-05-26 | 2022-05-24 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Lactam compound as FXR receptor agonist |
| KR102400183B1 (ko) | 2017-07-06 | 2022-05-18 | 수안주 바이오파마슈티컬 컴퍼니 리미티드 | Fxr 작용제 |
| CN109053751A (zh) | 2018-08-30 | 2018-12-21 | 成都海博锐药业有限公司 | 具有螺环结构的fxr调节剂 |
-
2020
- 2020-09-01 CA CA3153062A patent/CA3153062A1/en active Pending
- 2020-09-01 WO PCT/IB2020/058114 patent/WO2021044287A1/en not_active Ceased
- 2020-09-01 US US17/639,862 patent/US20220340668A1/en active Pending
- 2020-09-01 EP EP20768112.3A patent/EP4025248A1/en active Pending
- 2020-09-01 MX MX2022002636A patent/MX2022002636A/es unknown
- 2020-09-01 AU AU2020341135A patent/AU2020341135A1/en active Pending
- 2020-09-01 KR KR1020227007746A patent/KR20220054608A/ko active Pending
- 2020-09-01 BR BR112022003884A patent/BR112022003884A2/pt unknown
- 2020-09-01 CN CN202080062007.XA patent/CN114630681A/zh active Pending
- 2020-09-01 JP JP2022513902A patent/JP7663559B2/ja active Active
-
2022
- 2022-02-23 IL IL290852A patent/IL290852A/en unknown
- 2022-03-02 JO JOP/2022/0057A patent/JOP20220057A1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021044287A1 (en) | 2021-03-11 |
| JOP20220057A1 (ar) | 2022-03-02 |
| JP7663559B2 (ja) | 2025-04-16 |
| US20220340668A1 (en) | 2022-10-27 |
| BR112022003884A2 (pt) | 2022-05-31 |
| CA3153062A1 (en) | 2021-03-11 |
| AU2020341135A1 (en) | 2022-04-07 |
| EP4025248A1 (en) | 2022-07-13 |
| IL290852A (en) | 2022-04-01 |
| JP2022547452A (ja) | 2022-11-14 |
| KR20220054608A (ko) | 2022-05-03 |
| CN114630681A (zh) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022002636A (es) | Tratamiento de la enfermedad o trastorno hepatico que comprende los antagonistas del receptor de actrii. | |
| CR20190311A (es) | Composiciones para tratar afecciones inflamatorias | |
| CL2017002686A1 (es) | Métodos para tratar o prevenir dolor de cabeza por migraña | |
| CR20190468A (es) | Métodos para tratar enfermedades y trastornos mediados por completo | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| CL2021001609A1 (es) | Régimen de dosificación y combinación farmacéutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona | |
| MX390954B (es) | Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| NI201700032A (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del higado graso no alcohólico | |
| AR104812A1 (es) | Combinaciones terapéuticas y métodos para tratar neoplasias | |
| DOP2016000133A (es) | Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este | |
| EA201691454A1 (ru) | Композиции придопидина модифицированного высвобождения | |
| BR112014016672A8 (pt) | compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo | |
| MX394875B (es) | Terapia combinada para trastornos neuropsiquiatricos sensibles al antagonista de nmdar. | |
| MX2020012979A (es) | Métodos para aumentar la exposición al plasma de sepiapterina. | |
| MX376312B (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| CL2020002465A1 (es) | Método de tratamiento de enfermedad fibrótica | |
| CL2011002416A1 (es) | Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit. | |
| BR112021006223A2 (pt) | regime de dosagem para antagonistas de inibidor da via de fator tecidual (tfpi) | |
| PH12021550671A1 (en) | Prodrugs of cgrp antagonists | |
| BR112019005985A2 (pt) | composições de combinação compreendendo agonistas de fxr para tratar ou prevenir uma doença ou distúrbio fibrótico, cirrótico | |
| CL2021000585A1 (es) | Métodos para tratar la pancreatitis | |
| CL2019000625A1 (es) | Combinación de agonistas de fxr. | |
| BR112023026992A2 (pt) | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer | |
| BR112018000568A2 (pt) | antagonistas do receptor 5-ht6 para uso no tratamento da doença de alzheimer com apatia como comorbidade |